Andy Acker, CFA

Portfolio Manager
Andy Acker, CFA | Janus Henderson Investors

Andy Acker is a Portfolio Manager at Janus Henderson Investors responsible for managing the Global Life Sciences and Biotechnology strategies since 2007 and 2018, respectively. He also leads the firm’s Health Care Sector Research Team. Mr. Acker was assistant portfolio manager on the Global Life Sciences strategy from 2003 to 2007. He joined Janus in 1999 as a research analyst focused on companies in the biotechnology and pharmaceutical industries. Prior to this, he worked as a strategy consultant for the Boston Consulting Group and as a health care analyst for Morgan Stanley Venture Partners.

Mr. Acker received his bachelor of science degree in biochemical sciences from Harvard University, graduating magna cum laude and Phi Beta Kappa. He also earned an MBA with honors from Harvard Business School. Mr. Acker holds the Chartered Financial Analyst designation and has 24 years of financial industry experience.

Articles Written

COVID-19: Understanding the Science & Investment Implications (Part I)

COVID-19: Understanding the Science & Investment Implications (Part I)

A new video series from our health care team offers unique insight into how the pandemic is affecting different sectors of the economy.

Innovation and Health Care Amid COVID-19

Innovation and Health Care Amid COVID-19

How the coronavirus pandemic is shining a spotlight on the long-term potential of health care’s advanced research and technology.

Coronavirus and Health Care: A Complex Dynamic

Coronavirus and Health Care: A Complex Dynamic

As the coronavirus spreads, some health care companies have warned about falling revenues, while other firms are working on a treatment – and seeing their stocks rise.

Market GPS: The Outlook for Health Care Stocks in 2020

Market GPS: The Outlook for Health Care Stocks in 2020

After a volatile 2019, what can health care investors expect in the new year?

Can Biotech Bounce Back?
Quick Views Healthcare

Can Biotech Bounce Back?

Portfolio Manager Andy Acker discusses biotechnology’s sell-off this year and why he thinks investors should not give up on the sector.

Can Biotech Bounce Back?
Quick Views Healthcare

Can Biotech Bounce Back?

Portfolio Manager Andy Acker discusses biotechnology’s sell-off this year and why he thinks investors should not give up on the sector.

What Knowledge Shared means for you

At Janus Henderson, we believe in the sharing of expert insight for better investment and business decisions.

We call this ethos Knowledge Shared.

HGI_DNA_1
Taking a Balanced Approach to Investing in Cancer Therapy
Quick Views Featured Healthcare

Taking a Balanced Approach to Investing in Cancer Therapy

There’s more than one way to gain exposure to advances in oncology, say Andy Acker, Dan Lyons and Luyi Guo of the Global Life Sciences Team.

Drug Pricing Reform Shifts Course
Quick Views Healthcare

Drug Pricing Reform Shifts Course

After hitting roadblocks last week, the effort to lower drug prices in the U.S. is changing course, with implications for investors.

M&A Activity a Favored Prescription for Biopharmaceutical Companies
Quick Views Technology

M&A Activity a Favored Prescription for Biopharmaceutical Companies

Andy Acker discusses how biopharmaceutical companies utilize M&A strategies to fill product pipelines and maintain steady cash flows.

Subscribe for relevant insights delivered straight to your inbox

Mid-Year Market GPS: Disruptive Forces

Mid-Year Market GPS: Disruptive Forces

Focusing on secular growth drivers as the technology and health care sectors experience rapid change – and bouts of volatility.

Global Sector Views

Read the latest insights from our research team and learn how they are navigating the opportunities and risks within each sector.